Clinical trials: Obesity, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Obesity
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Obese, Overweight
A Study of SA030 Injection in Overweight or Obese Participants
This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight…
- Trial name
- NCT07479862
- Testing
- SA030 Injection
- Where
- 2 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Siran Biotechnology Co.,Ltd.
Overweight or Obesity
A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose and multiple doses of SYH2082 Injection in healthy participants.
- Trial name
- NCT07532655
- Testing
- SYH2082 Injection
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Two Formulations of…
- Trial name
- NCT07893093
- Testing
- ASC36 Injection A, for subcutaneous use, ASC36 Injection B, for subcutaneous use
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Pain Management, Overweight , Obesity
Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing Bariatric Surgery
This single-center, stratified randomized double-blind trial tests tegileridine, a new pain drug, for pain relief after weight-loss surgery. Researchers will compare tegileridine with standard opioid pain medicine.
- Conditions
- Pain Management, Overweight , Obesity, Respiration; Sleep Disorder
- Trial name
- NCT07844512
- Testing
- Tegileridine (tegileridine fumarate injection, IV), Sufentanil
- Volunteers
- 148 people
- Sponsor
- The First Hospital of Jilin University
Overweight, Obesity
A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity
The purpose of this clinical study is to test how taking zenagamtide tablets with different meal/water variations affects how much zenagamtide enters the bloodstream in people who have overweight or obesity.
- Trial name
- NCT07815067
- Testing
- Zenagamtide injection, Zenagamtide tablet
- Where
- Germany
- Volunteers
- 320 people
- Sponsor
- Novo Nordisk A/S
Obesity, Chronic Kidney Disease
Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access
Obesity has a serious impact on people's health and quality of life. For those with advanced kidney disease (i.e. approaching the need for dialysis), obesity is especially problematic - obesity can not only lead to worsening…
- Conditions
- Obesity, Chronic Kidney Disease, Chronic Renal Disease, CKD
- Trial name
- PIVOT (NCT07858331)
- Testing
- Semaglutide, Virtual Weight Management Coaching
- Where
- 2 sites in Canada
- Volunteers
- 880 people
- Sponsor
- Kristin Clemens
Morbid Obesity
Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher
Patients with BMI 60 kg/m² or higher are the hardest operations in bariatric surgery. Thick abdominal wall, massive hepatomegaly, reduced working space, fragile fatty tissue, higher conversion and complication rates.
- Trial name
- NCT07859137
- Testing
- Semaglutide weekly injection
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
Morbid Obesity
Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)
Metabolic and bariatric surgery (MBS) is the most effective durable treatment for severe obesity, yet a clinically meaningful proportion of patients experience recurrent weight gain after an initially successful operation.
- Trial name
- NCT07859150
- Testing
- Semaglutide weekly injection, Placabo
- Where
- Egypt
- Volunteers
- 104 people
- Sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
Morbid Obesity
Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain
Recurrent weight gain affects 15% to 40% of patients after metabolic and bariatric surgery (MBS). SG is the most performed operation worldwide, and long-term regain after SG is well documented.
- Trial name
- NCT07859163
- Testing
- Semaglutide weekly injection
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
Morbid Obesity
Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery
Every course of obesity pharmacotherapy ends. Cost, supply, pregnancy plans, side effects, or the patient's own wish. In Egypt, cost alone makes discontinuation the rule, not the exception.
- Trial name
- NCT07859176
- Testing
- Semaglutide weekly injection
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
Morbid Obesity
Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery
Roughly one patient in five never reaches the expected weight loss after MBS, and long-term regain after SG is well documented. These patients are identifiable at the 12-month visit.
- Trial name
- NCT07859189
- Testing
- Semaglutide weekly injection
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
Obesity, Normal Weight
Hypothalamic GLP-1 Response in Healthy Weight and Obesity
The goal of this clinical trial is to learn how the gut hormone glucagon-like peptide-1 (GLP-1) helps the brain sense sugar. It includes adults with healthy weight and adults with obesity.
- Conditions
- Obesity, Normal Weight, Glucose Intolerance
- Trial name
- NCT07854886
- Testing
- Gastric glucose, GLP-1(7-36)NH2, Exendin(9-39)NH2
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
The goal of this clinical trial is to learn if a combination treatment of a hormonal intrauterine device (LNG-IUD), semaglutide, and a structured weight loss program can treat endometrial atypical hyperplasia or grade 1…
- Conditions
- Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer
- Trial name
- SWIFT (NCT07820358)
- Testing
- Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- The Methodist Hospital Research Institute
Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
- Trial name
- NCT07836270
- Testing
- Ecnoglutide Injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Overweight and Obesity
A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE103 injection in healthy overweight/obese participants or healthy postmenopausal women.
- Trial name
- NCT07230496
- Testing
- LAE103 injection, LAE102 injection in combined with LAE103 injection, Saline
- Where
- 2 sites in Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Laekna Limited
Cardiac Surgery
Epicardial Fat Immunity extRa Cellular vesicleS HearT
The FIRST study is a monocentric observational pilot study investigating the role of extracellular vesicles (EVs) derived from epicardial adipose tissue (EAT) in cardiovascular complications associated with obesity.
- Trial name
- FIRST (NCT07817667)
- Testing
- Epicardial adipose tissue biopsy, Thoracic subcutaneous adipose tissue biopsy
- Volunteers
- 100 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Obesity
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
The main purpose of this study is to evaluate the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity.
- Trial name
- NCT07812597
- Testing
- zovaglutide Arm 1, zovaglutide Arm 2, semaglutide
- Where
- 16 sites in China
- Volunteers
- 210 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obesity and Overweight, Binge Eating Disorder
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
The purpose of this study is to assess the efficacy and safety of tirzepatide in adults with obesity and binge-eating disorder, comparing tirzepatide against placebo and lisdexamfetamine dimesylate.
- Trial name
- LIBERATE (NCT06847399)
- Testing
- Tirzepatide, Lisdexamfetamine Dimesylate, Guided self-help cognitive behavioral therapy
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Johns Hopkins University
Overweight or Obesity
Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.
To evaluate the efficacy and safety of SYH2069 injection compared with placebo in obese Non-diabetic Participants after 28 weeks of treatment.
- Trial name
- NCT07803991
- Testing
- SYH2069 Injection
- Where
- China
- Volunteers
- 360 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Diabete Type 2, Insulin Resistant Diabetes (Mellitus)
Study Evaluating the Safety and Feasibility of Endoscopic Duodenal Injections of Autologous Mesenchymal Stem Cells
Type 2 Diabetes Mellitus (T2DM) pathogenesis increasingly involves "diabetic duodenopathy," characterized by proximal intestinal immune and epithelial dysregulation.
- Conditions
- Diabete Type 2, Insulin Resistant Diabetes (Mellitus), Obesity
- Trial name
- STEM-DM (NCT07344324)
- Testing
- endoscopic duodenal injection of ADMSCs
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS